Skip to main content
Premium Trial:

Request an Annual Quote

NeoGenesis Signs Discovery Collaboration with Amgen

NEW YORK, Aug. 4 (GenomeWeb News) - Chemical genomics firm NeoGenesis Pharmaceuticals said today that it has signed a multi-year drug discovery collaboration agreement with Amgen.


NeoGenesis will use its ALIS (Automated Ligand Identification System) platform along with its compound libraries and lead optimization technologies in the project, which will focus on the discovery of small-molecule drugs for cancer, neurodegenerative diseases, and inflammatory diseases.


The company will receive research funding, milestone payments, and royalties based on the successful development of drug candidates.


NeoGenesis, headquartered in Cambridge, Mass., has similar partnerships with Aventis Pharma, Biogen, Celltech, Japan Tobacco, Merck, Mitsubishi Pharma, Pfizer, Schering-Plough, and Tularik.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.